Topic:

Chutes and Ladders

Latest Headlines

Latest Headlines

Management theory put in play as India's Cipla eyes expansion abroad

A new management structure at Mumbai-based Cipla promises a high-stakes effort to help the Indian drugmaker abroad after an active spurt of acquisitions in 2015 as well as management shuffles.

Australia's Brandon Capital stakes a claim in Bay Area with new office

Melbourne-based venture capital fund Brandon Capital Partners has opened a Palo Alto office, hiring a veteran as a partner as part of its aim to bring promising Australian pharma and medical tech to the market.

Former CFO Schiller to lead Valeant during CEO Pearson's medical leave

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

With Shkreli out, new Turing boss slashes jobs, hunts for a CEO

With former Turing founder and CEO Martin Shkreli facing federal fraud and looting charges, the biotech's new helmsman is cutting costs and hunting for someone who'd like to try to salvage the biotech.

Shkreli resigns from Turing Pharma, replaced by a longtime associate with Retrophin ties

Martin Shkreli, arrested yesterday on charges of securities fraud, has resigned from his CEO post at Turing Pharmaceuticals. In his stead, Turing appointed Chairman Ron Tilles, a longtime Shkreli associate who allegedly played a role in what the FBI called a "Ponzi-like" scheme at the pair's former company.

Paris Panayiotopoulos takes the reins at Ariad

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Sanofi nears hire of Morgan Stanley banker as M&A head: Bloomberg

If Sanofi intends to follow through with the strategy new CEO Olivier Brandicourt laid out last month, it has some serious dealmaking to do--and on that front, it may soon be bringing in backup.

Agios Pharmaceuticals COO Higgons heads for the door

Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Eric Sagonowsky (email) or...

Sprout CEO Whitehead departs Valeant

In August, female libido drug maker Sprout agreed to a $1 billion buyout from Valeant that would make it a division of the Canadian pharma run by its current CEO, Cindy Whitehead. Now, though--less than four months later--Whitehead is on her way out.

Beleaguered Daiichi Sankyo shuttering German antibody business

It's been rough lately for Daiichi Sankyo, and now, things are going from bad to worse. The beleaguered Japanese drugmaker is shuttering its German antibody subsidiary, months after it announced that it would cut half its U.S. workforce in a bid to revive business and prepare for the patent loss for its best-selling drug.  
'